How to Structure a Deal Between DTx and Pharma Companies?

Structuring a deal between pharmaceutical companies and digital therapeutics (DTx) companies can be complex, and the specifics will depend on various factors, including the therapeutic area to which the deal pertains, market size, and development stage of the DTx solution. Despite the potential benefits of pharma-DTx partnerships, most collaborations thus far have remained at the pilot stage, with limited success. In this meeting, we will explore how DTx companies can best approach pharma to establish sustainable partnerships, and how pharma should be evaluating DTx. Register now to be part of this roundtable discussion where we will delve into: